This study compared adverse event (AE) reporting patterns of tirzepatide and semaglutide using data from the FAERS spontaneous reporting database. The analysis covered reports from May 2022 to June 2026.
Key Clinical Findings
A total of 151,654 tirzepatide reports and 64,987 semaglutide reports were examined. The study investigated how reporter identity – specifically, the distinction between general population and healthcare professional (HCP) reporters – influenced the prominence of reported signals. Four methods were used to determine signal convergence, alongside the Benjamini-Hochberg false discovery rate procedure to ensure signal robustness. Comparisons were made using the ratio of reporting odds ratios (RORR) with 95% confidence intervals.
Differential Reporting Patterns
In the general population, only semaglutide met the stringent four-method criteria for gastrointestinal (GI) and metabolic disorders, with RORR values of 0.58 and 0.59 respectively. Pancreatitis signals were observed for both agents, but the difference attenuated within the Type 2 Diabetes Mellitus (T2DM) indication. Diabetic ketoacidosis signals were exclusively reported for semaglutide in the HCP cohort, with a RORR of 3.52. Tirzepatide demonstrated higher reporting of hypoglycaemia, with a RORR of 1.91. Within the HCP cohort, tirzepatide’s GI RORR increased to 2.53, and semaglutide exhibited signals for eye disorders with a RORR of 2.61. All sensitivity analyses, including stratification by indication, seriousness, geography, and calendar quarter, confirmed the directional stability of these comparative reporting patterns across various subgroups. The findings highlight distinct AE reporting patterns between the two agents, influenced by reporter type. These results are considered hypothesis-generating and require further confirmation with defined exposure denominators.